Antimycobacterial activity of quaternary pyridinium salts and pyridinium N-oxides--review. 2013

Martin Krátký, and Jarmila Vinšová
Department of Chemistry, Faculty of Science, University of Hradec Králové, Rokitanského 62, 500 03 Hradec Králové, Czech Republic.

The treatment of tuberculosis and other mycobacterioses is still a major world health problem and new antimycobacterial compounds unrelated to approved drugs are in demand. Quaternary ammonium salts have revealed many usable properties especially as antimicrobials; they are widely used as disinfection and antiseptic agents. Some of these compounds, including pyridinium salts, have revealed substantial antimycobacterial action, although the presence of the cationic nitrogen itself is not sufficient for activity. A long Nalkyl chain is also not necessary for antimycobacterial activity, although it is associated with improved activity. Compounds that have shown significant in vitro activity, e.g., cetylpyridinium, N-(substituted alkyl)pyridinium salts, 3-[(5- cyclopentylpentyl)(substituted phenyl)amino]-1-methylpyridinium iodides or pyridinium alkyl ethers of steroids (good activity with minimum inhibitory concentrations - MIC from 0.4 μg/mL). However, most pyridinium salts have mild or moderate activity against fastand/ or slow-growing mycobacteria, including N-methylated isoniazids or pyridinium-based oximes. Moreover, a pyridinium ring is present in some cefalosporines (e.g., cefaloridine, ceftazidime and cefsulodine) with antimycobacterial properties. The N-oxidation of pyridine mostly resulted in retained or increased minimum inhibitory concentrations. Additionally, the action of pyridinium N-oxides against mycobacteria is not especially robust. The mechanism of action of pyridinium compounds remains elusive, but the inhibition of some mycobacterial enzymes has been described for a few derivatives.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011726 Pyridinium Compounds Derivatives of PYRIDINE containing a cation C5H5NH or radical C5H6N. Compounds, Pyridinium
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular

Related Publications

Martin Krátký, and Jarmila Vinšová
January 2008, Journal of oleo science,
Martin Krátký, and Jarmila Vinšová
March 1993, Journal of pharmaceutical sciences,
Martin Krátký, and Jarmila Vinšová
March 2008, Journal of applied microbiology,
Martin Krátký, and Jarmila Vinšová
October 1990, Zentralblatt fur Hygiene und Umweltmedizin = International journal of hygiene and environmental medicine,
Martin Krátký, and Jarmila Vinšová
June 2005, Bioorganic & medicinal chemistry letters,
Martin Krátký, and Jarmila Vinšová
July 1951, Comptes rendus hebdomadaires des seances de l'Academie des sciences,
Martin Krátký, and Jarmila Vinšová
October 1981, Yao xue xue bao = Acta pharmaceutica Sinica,
Martin Krátký, and Jarmila Vinšová
January 2007, Mikrobiolohichnyi zhurnal (Kiev, Ukraine : 1993),
Martin Krátký, and Jarmila Vinšová
April 2006, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!